Novo Nordisk tops KRW 14T in sales, thanks to Wegovy

By Whang, byung-woo | translator Hong, Ji Yeon

24.11.08 05:02:55

가나다라 0

Posted sales of KRW 14.3378 trillion in Q3, 22% increase in the North American market-21% increase globally

New products such as Ozempic and Wegovy show steady growth in sales

Novo Nordisk's 2024 sales growth 23-27%...lowers its sales goal

Novo Nordisk has recorded a strong sales performance in Q3, driven by the steady growth of its major products, including Wegovy and Ozempic.

According to Novo Nordisk's business reports on November 6th (local time), they recorded US$10.267 billion (KRW 14.3378 trillion) in Q3 sales, up 21% from the previous year.

Its operating profit amounted to US$4.877 billion (KRW 6.8112 trillion), up 26% from 2023, and it recorded US$3.9325 billion (KRW 5.4921 trillion) in net revenues, up 21% from 2023.

By region, the sales rose by 22% to US$3.85297 billion (KRW 5.4861) in the North American market and by 21% to US$2.59707 billion (KRW 3.6275 trillion) in the global market, excluding

Whang, byung-woo(tuai@dailypharm.com)

If you want to see the full article, please JOIN US (click)